U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06909253) titled 'Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis' on March 27.
Brief Summary: The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Study Start Date: July 01, 2025
Study Type: OBSERVATIONAL
Condition:
Myasthenia Gravis, Generalized
Intervention:
DRUG: Ravulizumab
Ravulizumab, concentrate for solution for infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Published by HT Digital Content Services with permission from Health Daily Digest....